Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Viking Therapeutics (0VQA) Share Price & Analysis

0VQA Stock Chart & Stats

$26.84-$0.04(-0.15%)
At close: 4:27 PM GMT
$25$30$35$403 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$26.22 - $27.84
52-Week Range
$23.93 - $45.90
Previous Close
$26.52
Volume
N/A
Average Volume (3M)
42.26K
Market Cap
$3.48B
Enterprise Value
$3.14B
Total Cash (Recent Filing)
$959.81M
Total Debt (Recent Filing)
$254.69M
Price to Earnings (P/E)
―
Beta
0.81
Next Earnings
Feb 10, 2027 (Est.)
EPS Estimate
-1.38
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Pipeline Progress

Advancing both injectable and oral VK2735 programs into late-stage trials strengthens Viking’s development platform and expands potential product formats. Fully enrolled studies and a new registration program create multiple upcoming clinical milestones that could support future commercialization if results and regulatory reviews are favorable.

Efficacy And Flexible Dosing

Sustained weight loss with every-other-week and monthly regimens could differentiate VK2735 beyond initial efficacy by addressing long-term maintenance and dosing convenience. These findings support a broader product profile, although confirmation in later-stage studies remains necessary before they can underpin an approved label.

Funding Runway

The strengthened cash position gives Viking substantial resources to continue expensive Phase III development, advance VK3019, and build commercial capabilities without relying immediately on another financing. That liquidity supports execution over the next several quarters, though ongoing spending will determine how long the runway lasts.

Bears Say

No Commercial Revenue And Widening Losses

Viking has not yet established a commercial revenue stream to offset research and operating costs, leaving its financial outlook dependent on clinical progress and future product approval. Rapidly widening losses increase the amount of capital required before the business can potentially become self-funding.

Heavy Cash Burn

Large and deteriorating cash outflows make continued financing capacity central to Viking’s ability to complete development programs and prepare for launch. Persistent burn can reduce strategic flexibility and increase future equity or debt needs, even though the recent financing temporarily improves available liquidity.

Rising Leverage

The move from minimal historical debt to $255 million adds fixed financial obligations to a company that is still loss-making and cash-consuming. Higher leverage can narrow flexibility during clinical delays or regulatory setbacks and may compete with research and commercialization spending for future capital.

Viking Therapeutics News

0VQA FAQ

What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest share price was $23.93 and its highest was $45.90 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $3.48B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s next earnings report is estimated for Feb 10, 2027 (not yet confirmed), which is in 100 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Oct 28, 2026. The company reported -$1.55 earnings per share for the quarter, missing the consensus estimate of -$1.063 by -$0.487.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -1.38.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 127,522,190 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$1.55 in its last earnings report, missing expectations of -$1.063. Following the earnings report the stock price went up 6.122%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Hedge funds hold Viking Therapeutics shares: the largest hedge-fund position in Viking Therapeutics is 492,031,766 shares, and hedge funds increased their holdings by 3.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology